Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
103Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $170.44M | $-193.88M | $-3.76 |
| 2024 | $83.33M | $-227.10M | $-4.59 |
| 2023 | $90.24M | $-263.49M | $-6.02 |
| 2022 | $112.72M | $-280.32M | $-6.50 |
| 2021 | $470.35M | $127.84M | $3.01 |
Social Signal Score
Earnings
Thu, Nov 5(in 3 months)
Consensus estimate $-1.36 per share
Typical surprise -22.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.43 vs $0.08beat
- Thu, May 14$-1.72 vs $-1.36miss
- Thu, Mar 5$-1.30 vs $-1.01miss
- Thu, Nov 6$-1.20 vs $-1.38beat
- Thu, Aug 7$-1.38 vs $-1.13miss
- Mon, May 12$0.12 vs $0.41miss
Estimates and results for RGNX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
RGNXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsseekingalpha.com·4d ago·Neutral
Regenxbio's Multi-Catalyst Setup Is Hard To Ignore (Rating Upgrade) Regenxbio Inc. delivered a strong quarter, driven by milestone revenue, with GAAP EPS of $0.43 and revenue up 407% YoY. RGNX now holds $313 million in pro forma cash, funding operations into Q4 2027 and removing near-term financing overhang. Multiple late-stage catalysts—including RGX-202, pivotal wet AMD data, and RGX-121 resubmission—are stacked over the next 12–18 months.
View source ↗